FDA — authorised 30 October 2018
- Application: BLA761071
- Marketing authorisation holder: SANDOZ INC
- Local brand name: HYRIMOZ
- Indication: INJECTABLE — INJECTION
- Status: approved
🇺🇸 HYRIMOZ in United States
FDA authorised HYRIMOZ on 30 October 2018
Marketing authorisation
HYRIMOZ in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Other approved in United States
Frequently asked questions
Is HYRIMOZ approved in United States?
Yes. FDA authorised it on 30 October 2018.
Who is the marketing authorisation holder for HYRIMOZ in United States?
SANDOZ INC holds the US marketing authorisation.